Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Decreases By 46.4%

Xenetic Biosciences Inc (NASDAQ:XBIO) was the recipient of a large decrease in short interest in March. As of March 15th, there was short interest totalling 4,500 shares, a decrease of 46.4% from the February 28th total of 8,400 shares. Based on an average trading volume of 7,100 shares, the days-to-cover ratio is presently 0.6 days. Approximately 0.4% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “neutral” rating on shares of Xenetic Biosciences in a research note on Thursday, March 20th.

Xenetic Biosciences Trading Up 0.8 %

Shares of Xenetic Biosciences stock opened at $3.30 on Friday. The business’s fifty day simple moving average is $3.91 and its 200 day simple moving average is $3.98. Xenetic Biosciences has a 12 month low of $2.78 and a 12 month high of $5.20. The firm has a market capitalization of $5.08 million, a P/E ratio of -1.24 and a beta of 2.17.

Xenetic Biosciences (NASDAQ:XBIO) last released its earnings results on Tuesday, March 18th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.48). The business had revenue of $0.65 million for the quarter, compared to the consensus estimate of $0.18 million. Xenetic Biosciences had a negative return on equity of 49.51% and a negative net margin of 161.63%. Analysts predict that Xenetic Biosciences will post -1.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Xenetic Biosciences stock. Renaissance Technologies LLC increased its stake in Xenetic Biosciences Inc (NASDAQ:XBIO) by 61.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 25,550 shares of the company’s stock after purchasing an additional 9,700 shares during the quarter. Renaissance Technologies LLC owned approximately 1.66% of Xenetic Biosciences worth $102,000 at the end of the most recent quarter. 15.12% of the stock is owned by institutional investors.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.